Seeking Alpha

Pfizer to submit NDA for breast cancer treatment; shares higher

  • Pfizer (PFE +1.5%) will submit an FDA new drug application for the use of its Palbociclib drug, together with Letrozole, for the "treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer."
  • The decision stems from the results of Pfizer's Paloma-1 Phase 2 trial for Palbociclib/Letrozole. An NDA submission is expected in early Q3.
  • Pfizer is trading higher after coming off a halt. AstraZenaca (AZN +0.4%) investors are breathing a sigh of relief.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: